Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, TX 77030, USA.
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, TX 77030, USA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, TX 77030, USA; Department of Immunology. The University of Texas MD Anderson Cancer Center, TX 77030, USA.
Cell Rep Med. 2022 May 17;3(5):100642. doi: 10.1016/j.xcrm.2022.100642.
Derosa et al. demonstrated that intestinal Akkermansia muciniphila predicts vigorous response to immunotherapy in non-small-cell lung cancer. Baseline level of this microbe has better value than PD-L1 expression and represents a unique approach for stratifying patients that can benefit from immunotherapy.
德罗萨等人的研究表明，肠道阿克曼氏菌（Akkermansia muciniphila）可预测非小细胞肺癌对免疫治疗的强烈反应。这种微生物的基线水平比 PD-L1 表达更有价值，代表了一种独特的分层方法，可以筛选出能从免疫治疗中获益的患者。
